---
title: Jonas Mandel
subtitle: Senior Bioinformatics Scientist
image: photo_marseille2.jpg
about:
  template: trestles
  image-width: 12em
  image-shape: round
  links:
    - text: "{{< iconify logos:linkedin-icon >}} in/jonasmandel"
      url: "https://www.linkedin.com/in/jonasmandel"
    - text: "{{< iconify streamline-color:mail-send-email-message >}} jonas.mandel@gmail.com"
      url: "mailto:jonas.mandel@gmail.com"  
---

:::{.column-page}

<!---# [Jonas [Mandel]{.lighter-title .char-warning} [![](./photo_marseille2.jpg)]{.content-visible when-format="html"}]{.profile-img}--->

<!---
::: {.d-flex .justify-content-between .flex-wrap}
### Senior Bioinformatics Scientist
{{< fa at >}} [jonas.mandel@gmail.com](mailto:jonas.mandel@gmail.com) | {{< fa brands linkedin >}} [linkedin.com/in/jonasmandel](https://www.linkedin.com/in/jonasmandel/)
:::
--->

::: {.panel-tabset}
## [Resume]{.char-color}

### {{< iconify streamline-color:user-profile-focus >}} [About]{.char-color} me

Accomplished bioinformatics scientist with 14 years of experience in bioinformatics, omics data analysis, machine learning, and clinical biostatistics. Expert omics data analyst for RNAseq, scRNAseq, long-read sequencing, biomarker data analysis, GWAS. Expert R programmer with working knowledge of Python and proficiency in various bioinformatics & biostatistics methods & tools. Strong experience in scientific writing & communication for a variety of audiences (researchers, clinicians, investors). Focus areas: immuno-oncology, cardiology, neurology, rare diseases.


### {{< iconify streamline-color:workspace-desk >}} [Work]{.char-color} Experience

::: {.d-flex .justify-content-between .flex-wrap}
#### [Senior Bioinformatics Scientist]{.char-color} - Mnemo Therapeutics
*2021 - 2025, Paris*
:::

* Developed pipelines for detection of alternative splicing and cancer neoantigen prediction using RNAseq, scRNAseq, and long-read RNAseq (PacBio).
* Led integration of transcriptomics (>20K RNAseq samples) and immunopeptidomics databases (>1.5K samples) to generate target peptides libraries: >1.2K putative targets, leading to 8 validated peptide targets.
* Designed statistical analysis of neoantigen recurrence and peptide prioritization, instrumental for target mining strategy for vaccine and CAR-T development.
* Implemented long-read RNAseq pipeline for alternative splicing discovery & quantification based on IsoSeq3 & SQANTI.
* Coordinated cross-team efforts as work package lead for immunopeptidomics target mining; prepared scientific deliverables and presentations.
* Participated in the design & setup of the bioinformatics work environment from scratch: github, AWS, Trello, ...
* Company-wide support to develop automated data analysis and reporting.

::: {.d-flex .justify-content-between .flex-wrap}
#### [Biomarker Biostatistician]{.char-color} - Sanofi / Ividata
*2018 - 2021, Paris*
:::

* Led biomarker analyses in phase 2/3 trials (Sarilumab, Dupilumab, SAR440340) using RNAseq, SNP microarray, and proteomics (olink): SAP authoring & implementation with R, oversight of CROs, preparation of deliverables.
* Biomarker biostatistician and machine learning advisor in several R&D projects in oncology, cardiology, multiple sclerosis.
* Developed a shiny app for interactive reporting of omics biomarker data analysis.
* Participated in the development of R trainings “Introduction to R” and “Graphs in R” for Sanofi statisticians & programmers.

::: {.d-flex .justify-content-between .flex-wrap}
#### [Clinical Biostatistician]{.char-color} - Sanofi / Ividata
*2016 - 2018, Paris*
:::

* GMA Study biostatistician for phase 3b clinical trial (Alirocumab, hypercholesterolemia): authoring SAP and TLFs specs, coordination with CRO & clinical team to prepare of deliverables (KRM, CSR), supervision & QC of CRO’s activities.
* Led the biostatistics & data analysis strategy for the Alirocumab publication program, overseeing data mining and post-hoc analyses of 14 pooled clinical trials to generate scientific insights and support publications in peer-reviewed journals.

::: {.d-flex .justify-content-between .flex-wrap}
#### [Biostatistician & Computational Genomics Scientist]{.char-color} - Pharnext
*2012 - 2015, Paris*
:::

* Led design & implementation of a workflow for GWAS data imputation and analysis to discover disease-specific genomic alterations.
* Designed & wrote SAP for Phase II/III clinical trials with adaptive designs, interim futility and power analysis, procedures for multiple endpoints. Meta-analysis of clinical trials.
* Conducted biomarker statistical analysis for in-house clinical trials, including reportings and presentations for internal and external stakeholders (scientific & business).

::: {.d-flex .justify-content-between .flex-wrap}
#### [Biostatistics & Bioinformatics research engineer]{.char-color} - Institut Curie / INSERM U900
*2009 - 2012, Paris*
:::

* Performed omics statistical analyses (gene microarray, RNAseq, exome seq, SNP array) for various cancer research projects.
* Development automated workflows for omics data analysis.
* Participated to developing internal R programming training initiatives.
* 

### {{< iconify streamline-color:target >}} [Skills]{.char-color}

#### [Biostatistics & Data Science]{.char-color}
* **Statistical modelling & inference:** generalized linear model, mixed effects model, survival analysis, meta-analysis, PLS, principal component regression, interim analysis for clinical trials, conditional power analysis.
* **Multivariate statistics:** PCA, PLS, t-SNE, UMAP, multiple correspondence analysis, factor analysis.
* **Machine learning:** supervised classification & regression (LDA, SVM, Lasso / Elastic Net, boosting, bagging, random forests, XGBoost, …), unsupervised clustering (hierarchical clustering, k-means, DBSCAN, gaussian mixture models, …).

#### [Omics & Bioinformatics]{.char-color}
* **Transcriptomics (RNAseq, scRNAseq):** alignment, normalization, differential analysis, splicing detection & quantification.
* **Long-read sequencing (PacBio):** transcript identification, isoform quantification, differential analysis.
* **Genomics (WGS/WES):** variant calling, CNV analysis, fusion gene detection.
* **SNP microarrays & GWAS:** imputation, association testing.
* **Pathway enrichment:** GSA/GSEA.

#### [Bioinformatics tools & workflows]{.char-color}
* **Tools:** STAR, Seurat, StringTie, Samtools, NetMHCpan, DeepTMHMM, PLINK, IsoSeq3, SQANTI, tappAS, BLAST.
* **Workflow development:** Nextflow, Docker, Galaxy.

#### [Programming & DataViz]{.char-color}
R (tidyverse, ggplot2, mlr3, tidymodels, RMarkdown, Shiny), Python (pandas, seaborn, scikit-learn, matplotlib)

#### [Collaboration & Project Management]{.char-color}
Git/GitHub, Trello, Teams, agile coordination, cross-functional communication

#### [Languages]{.char-color}
English (fluent), French (native), Spanish (good)


### {{< iconify streamline-color:graduation-cap >}} [Education]{.char-color}

#### [MS in Bioinformatics and Modelling]{.char-color}
*INSA Lyon, 2003 - 2008*

#### [Research internships]{.char-color}
* Cellular automaton modeling of the dynamics of epidemics – *University of Amsterdam, 2008*
* Mathematical modelling of the effect of antibiotic dose on pneumococcus resistance to antibiotics – *Institut Pasteur, 2007*

#### [Trainings]{.char-color}
Time management (*Cegos, 2024*), Project management with Git & GitHub (*ArData, 2022*), Docker (*Aneo, 2023*), Machine learning & DataViz in Python (*DataScientest, 2020*).


### {{< iconify streamline-color:like-1 >}} [Interests]{.char-color}
* Theater & acting
* Hiking / running
* Sociology, philosophy
* Science fiction litterature

## {{< iconify streamline-color:news-paper >}} [Publications]{.char-color}
<p style="font-size:0.7em;"> 
* **Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.** Nabirotchkin S, Bouaziz J, Glibert F, <u>Mandel J</u>, Foucquier J, Hajj R, Callizot N, Cholet N, Guedj M, Cohen D. J Alzheimers Dis. 2022;88(4):1585-1603. [doi: 10.3233/JAD-220120](https://doi.org/10.3233/JAD-220120).
* **Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab.** Vallejo-Vaz AJ, Leiter LA, Del Prato S, Taskinen MR, Müller-Wieland D, Bujas-Bobanovic M, Letierce A, <u>Mandel J</u>, Samuel R, Ray KK. Eur J Prev Cardiol. 2020 Oct;27(15):1663-1674. [doi: 10.1177/2047487320905185](https://doi.org/10.1177/2047487320905185).
* **Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.** Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, <u>Mandel J</u>, Samuel R, Bujas-Bobanovic M, Leiter LA. Cardiovasc Diabetol. 2019 Nov 9;18(1):149. [doi: 10.1186/s12933-019-0951-9.](https://doi.org/10.1186/s12933-019-0951-9)
* **Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.** Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, <u>Mandel J</u>, Samuel R, Jones PH. Diabet Med. 2018;35:1742-1751. [doi: 10.1111/dme.13817](https://doi.org/10.1111/dme.13817).
* **Efficacy and Safety of Alirocumab Among Individuals with Diabetes Mellitus and Atherosclerotic Cardiovascular Disease in the Odyssey Phase 3 Trials.** Ganda OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, Koren A, <u>Mandel J</u>, Letierce A, Leiter LA. Diabetes Obes Metab. 2018 Oct;20(10):2389-2398. [doi: 10.1111/dom.13384.](https://doi.org/10.1111/dom.13384)
* **Efficacy and Safety of Lipid Lowering by Alirocumab in Chronic Kidney Disease.** Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, <u>Mandel J</u>, Banach M. Kidney Int. 2018 Mar 8. pii: S0085-2538(18)30055-3. [doi: 10.1016/j.kint.2017.12.011](https://doi.org/10.1016/j.kint.2017.12.011). 
* **Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).** McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, <u>Mandel J</u>, Davidson MH. Am J Cardiol. 2018 Apr 15;121(8):940-948. [doi: 10.1016/j.amjcard.2017.12.040](https://doi.org/10.1016/j.amjcard.2017.12.040).
* **No Evidence of Neurocognitive Adverse Events Associated with Alirocumab Treatment in 3340 Patients from 14 Randomized Phase 2 and 3 Controlled Trials: A Meta-Analysis of Individual Patient Data.** Harvey PD, Sabbagh MN, Harrison JE, Ginsberg HN, Chapman MJ, Manvelian G, Moryusef A, <u>Mandel J</u>, Farnier M. Eur Heart J. 2018 Feb 1;39(5):374-381. [doi: 10.1093/eurheartj/ehx661](https://doi.org/10.1093/eurheartj/ehx661).
* **Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.** Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, <u>Mandel J</u>, Samuel R, Henry RR. Diabetes Obes Metab. 2017 Dec;19(12):1781-1792. [doi: 10.1111/dom.13114](https://doi.org/10.1111/dom.13114).
* **Whole-genome profiling helps to classify phyllodes tumours of the breast.** Laé M, La Rosa P, <u>Mandel J</u>, Reyal F, Hupé P, Terrier P, Couturier J. J Clin Pathol. 2016 Dec; 69(12):1081-1087. [doi: 10.1136/jclinpath-2016-203684](https://doi.org/10.1136/jclinpath-2016-203684).
* **A Multi-Marker Genetic Association Test Based on the Rasch Model Applied to Alzheimer's Disease.** Wang W, <u>Mandel J</u>, Bouaziz J, Commenges D, Nabirotchkine S, Chumakov I, Cohen D, Guedj M; Alzheimer’s Disease Neuroimaging Initiative. PLoS One. 2015 Sep 17;10(9). [doi: 10.1371/journal.pone.0138223](https://doi.org/10.1371/journal.pone.0138223).
* **A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.** <u>Mandel J</u>, Bertrand V, Lehert P, Attarian S, Magy L, Micallef J, Chumakov I, Scart-Grès C, Guedj M, Cohen D. Orphanet J Rare Dis. 2015 Jun 13;10:74. [doi: 10.1186/s13023-015-0293-y](https://doi.org/10.1186/s13023-015-0293-y).
* **An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.** Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, Péréon Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, <u>Mandel J</u>, Milet A, Hajj R, Boudiaf L, Scart-Grès C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D. Orphanet J Rare Dis. 2014, Dec 18;9(1):199. [doi: 10.1186/s13023-014-0199-0](https://doi.org/10.1186/s13023-014-0199-0).
* **Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.** Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, Péréon Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, <u>Mandel J</u>, Milet A, Hajj R, Boudiaf L, Scart-Grès C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D. Orphanet J Rare Dis 2014, Dec 18;9(1):199. [doi: 10.1186/s13023-014-0201-x](https://doi.org/10.1186/s13023-014-0201-x).
* **Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics.** Opatowski L, <u>Mandel J</u>, Varon E, Boëlle PY, Temime L, Guillemot D. Antimicrob Agents Chemother 2010, Jun; 54(6):2330-7. [doi: 10.1128/aac.00331-09](https://doi.org/10.1128/aac.00331-09).
</p>
:::

:::
